News >

Adjuvant Setting in ER-Positive Breast Cancer Undergoing Transformation

Caroline Seymour
Published: Friday, Apr 13, 2018

Ruta D. Rao, MD

Ruta D. Rao, MD
Anastrozole has been shown to be an effective aromatase inhibitor (AI) for patients with estrogen receptor (ER)-positive breast cancer, but patients who remain on the therapy for longer than 2 years are at an increased risk of fractures, notes Ruta D. Rao, MD.

“The most common side effects patients experience are thoracalgia, myalgia, and hot flashes. However, the effect on bone density is the one side effect we, as physicians, worry about the most,” Rao explains.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication